Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 12—December 2020

Hypervirulent Klebsiella pneumoniae as Unexpected Cause of Fatal Outbreak in Captive Marmosets, Brazil

Juliana Mariotti Guerra, Natália Coelho Couto de A. Fernandes, Alessandra Loureiro Morales dos Santos, Joana de Souza Pereira Barrel, Bruno Simões Sergio Petri, Liliane Milanelo, Monique Ribeiro Tiba-Casas, Alcina Maria Liserre, Cláudia Regina Gonçalves, Cláudio Tavares Sacchi, José Luiz Catão-Dias, and Carlos Henrique CamargoComments to Author 
Author affiliations: Instituto Adolfo Lutz, São Paulo, Brazil (J.M. Guerra, N.C.C.A. Fernandes, A.L.M. dos Santos, J.S.P. Barrel, M.R. Tiba-Casas, A.M. Liserre, C.R Gonçalves., C.T Sacchi., C.H. Camargo); Universidade de São Paulo, São Paulo (N.C.C.A. Fernandes, A.L.M. dos Santos, J.L. Catão-Dias); Parque Ecológico do Tietê, São Paulo (B.S.S. Petri, L. Milanelo)

Main Article

Table 2

Antimicrobial susceptibility profile of highly virulent Klebsiella pneumoniae sequence type 86 strain P04 from a fatal epizootic among captive marmosets in Brazil, 2019*

Antimicrobial MIC, mg/L† Category
Amikacin <4.0 Susceptible
Ampicillin/sulbactam 8/4 Susceptible
Aztreonam <2 Susceptible
Cefepime <2 Susceptible
Cefotaxime <2 Susceptible
Ceftazidime <1.0 Susceptible
Ciprofloxacin <0.06 Susceptible
Colistin <0.25 Susceptible
Doripenem <0.5 Susceptible
Doxycycline 2.0 Susceptible
Gentamicin <1.0 Susceptible
Imipenem <1.0 Susceptible
Levofloxacin <1.0 Susceptible
Meropenem <1.0 Susceptible
Minocycline 4.0 Susceptible
Piperacillin/tazobactam <8/4 Susceptible
Polymyxin B <0.25 Susceptible
Sulfamethoxazole/trimethoprim <0.5/9.5 Susceptible
Ticarcillin/clavulanic Acid <16/2 Susceptible
Tigecycline‡ 0.5 Susceptible
Tobramycin <1.0 Susceptible

*Susceptibility determined by Sensititre (ThermoFisher,
†MIC values were categorized as susceptible, intermediate, or resistance following Clinical and Laboratory Standards Institute ( M100-S30 breakpoints (
‡Tigecycline breakpoint followed Food and Drug Administration recommendations.

Main Article

Page created: October 13, 2020
Page updated: November 19, 2020
Page reviewed: November 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.